title: Are all leucodepleted platelet concentrates equivalent? Comparison of Cobe LRS Turbo, Haemonetics MCS+ LD, and filtered pooled buffy-coat-derived platelets.
abstract: OBJECTIVE
  A number of technologies are available for the production of leucocyte-depleted platelet concentrates (PCs). This study compared the characteristics of PCs prepared by three commonly used techniques.
  
  
  METHODS
  In total, fifteen units of leucocyte-depleted PCs prepared by the Cobe LRS Turbo apheresis system, Haemonetics MCS+ with in-line filter and filtration of PCs derived from pooled buffy coats (BCs) were transferred into the same standard container. Markers to assess status/activation and microvesiculation of platelets as well as platelet injury were measured.
  
  
  RESULTS
  pH was well maintained in all types of PCs. The expression of CD62P was higher in Cobe LRS Turbo on day 1 but became equivalent between the three methods on day 5. A significant correlation was found between the expression of CD62P on platelet surface and soluble CD62P in the plasma. The degree of phosphatidylserine (PS) exposure was slightly higher in Cobe LRS Turbo and BC-PCs than Haemonetics MCS+ on day 1. However, on day 5 both apheresis PC values were higher than BC-PCs. A significant correlation was found between PS exposure and microvesiculation.
  
  
  CONCLUSIONS
  Leucodepleted PCs prepared by the three methods were different in terms of storage lesion and microvesiculation. The clinical significance of these findings remains to be investigated.
authors.affiliation: National Blood Service, London and SE Zone, London, UK. pranee.krailadsiri@nbs.nhs.uk
authors.forename: P
authors.initials: P
authors.lastname: Krailadsiri
authors.forename: J
authors.initials: J
authors.lastname: Seghatchian
mesh_terms: D017304:Annexin A5 / Q000378:metabolism; D015703:Antigens, CD / Q000378:metabolism; D001792:Blood Platelets / Q000737:chemistry / Q000166:cytology* / Q000276:immunology; D002462:Cell Membrane / Q000737:chemistry / Q000648:ultrastructure; D002469:Cell Separation / Q000295:instrumentation / Q000379:methods* / Q000592:standards; D002845:Chromatography / Q000379:methods; D004791:Enzyme Inhibitors / Q000378:metabolism; D005374:Filtration / Q000379:methods; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007962:Leukocytes; D019007:P-Selectin / Q000097:blood; D010718:Phosphatidylserines / Q000737:chemistry; D010974:Platelet Aggregation; D010976:Platelet Count; D019038:Platelet Glycoprotein GPIb-IX Complex / Q000378:metabolism; D010980:Platelet Membrane Glycoproteins / Q000378:metabolism; D010983:Plateletpheresis / Q000295:instrumentation / Q000379:methods / Q000592:standards; D060149:Tetraspanin 30; D013997:Time Factors
chemical_list: D017304:Annexin A5; D015703:Antigens, CD; C554586:CD63 protein, human; D004791:Enzyme Inhibitors; D019007:P-Selectin; D010718:Phosphatidylserines; D019038:Platelet Glycoprotein GPIb-IX Complex; D010980:Platelet Membrane Glycoproteins; D060149:Tetraspanin 30